Eitan Ram, Levine Douglas A, Abu-Rustum Nadeem, Sonoda Yukio, Huh Jae N, Franklin Corinna C, Stevens Tobey A, Barakat Richard R, Chi Dennis S
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Cancer. 2005 Apr 1;103(7):1397-401. doi: 10.1002/cncr.20920.
The objective of this study was to determine the impact of malignant pleural effusions on survival in patients with optimally debulked, advanced epithelial ovarian carcinoma.
The authors conducted a retrospective review of all patients with advanced epithelial ovarian carcinoma who underwent optimal primary cytoreduction at their institution between January 1987 and August 2000. Survival rates were compared between patients with optimally debulked Stage IIIC epithelial ovarian carcinoma and patients with optimally debulked Stage IV epithelial ovarian carcinoma (according to the International Federation of Gynecology and Obstetrics [FIGO] staging system) based on cytology-proven malignant pleural effusions.
Ninety-nine patients were identified, and 97 of those patients were evaluable. The group with Stage IIIC disease included 76 patients, and the group with Stage IV disease included 21 patients. The median age at diagnosis was 55 years (range, 26-88 years). The majority of patients received platinum-based chemotherapy after undergoing optimal primary cytoreduction. Age, tumor grade and histology, and the percentage of patients with ascites were similar in the two groups. The median survival rate was 58 months for patients who had Stage IIIC disease and 30 months for patients who had Stage IV disease (P = 0.016).
Although both groups underwent optimal cytoreduction in the abdomen/pelvis and were treated in a similar fashion, the median survival rate of patients with malignant pleural effusions was significantly shorter than the survival of patients without effusions. Many factors that led to or were manifested by pleural effusions, such as undetected bulky residual intrathoracic disease, may have been the cause for this survival difference. In the patients with effusions, one or more of these contributing factors may have led to the observed decreased survival rate, warranting further investigation.
本研究的目的是确定恶性胸腔积液对经最佳减瘤的晚期上皮性卵巢癌患者生存的影响。
作者对1987年1月至2000年8月期间在其机构接受最佳初次细胞减灭术的所有晚期上皮性卵巢癌患者进行了回顾性研究。根据细胞学证实的恶性胸腔积液,比较了经最佳减瘤的IIIC期上皮性卵巢癌患者和经最佳减瘤的IV期上皮性卵巢癌患者(根据国际妇产科联合会[FIGO]分期系统)的生存率。
共确定99例患者,其中97例可评估。IIIC期疾病组包括76例患者,IV期疾病组包括21例患者。诊断时的中位年龄为55岁(范围26 - 88岁)。大多数患者在接受最佳初次细胞减灭术后接受了铂类化疗。两组患者的年龄、肿瘤分级和组织学以及腹水患者的百分比相似。IIIC期疾病患者的中位生存率为58个月,IV期疾病患者为30个月(P = 0.016)。
尽管两组患者均在腹部/盆腔进行了最佳细胞减灭术且治疗方式相似,但有恶性胸腔积液患者的中位生存率明显短于无胸腔积液患者。许多导致胸腔积液或由胸腔积液表现出的因素,如未检测到的胸腔内大块残留病灶,可能是导致这种生存差异 的原因。在有胸腔积液的患者中,这些促成因素中的一种或多种可能导致了观察到的生存率下降,值得进一步研究。